Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam
(IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam
CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a
tertiary care hospital. The objectives of the study are to demonstrate successful treatment
of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to
analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to
historical clinical outcome data with CZA and MVB use at the same institution.